Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20969188 | 1.00 | MAPT (0.35) | MAPTTHRBMT-CO2ALOX5TRIM24 | |
| SCHEMBL27174143 | 0.93 | MT-CO2 (0.33) | MAPTTHRBMT-CO2ALOX5CA1 | |
| SCHEMBL27174124 | 0.86 | MT-CO2 (0.34) | MT-CO2ALOX5CA1CA2CA4 | |
| SCHEMBL27174116 | 0.80 | MT-CO2 (0.33) | MAPTTHRBMT-CO2ALOX5CA1 | |
| SCHEMBL4740702 | 0.78 | CA1 (0.37) | MAPTMT-CO2ALOX5CA1CA2 | |
| SCHEMBL22397285 | 0.78 | CA1 (0.42) | MAPTMT-CO2ALOX5CA1CA2 | |
| SCHEMBL12333841 | 0.78 | CA1 (0.42) | MAPTMT-CO2ALOX5CA1CA2 | |
| SCHEMBL895510 | 0.78 | CA1 (0.42) | MAPTMT-CO2ALOX5CA1CA2 | |
| SCHEMBL120444 | 0.78 | CA1 (0.42) | MAPTMT-CO2ALOX5CA1CA2 | |
| SCHEMBL11955 | 0.78 | CA1 (0.42) | MAPTMT-CO2ALOX5CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | NORTHWESTERN UNIVERSITY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | MYC, CDK4, CDKL3 | MAPT 4535/4885THRB 4376/4885MT-CO2 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.